Cardiac Models in Drug Discovery and Development: A Review

Critical Reviews in Biomedical Engineering

Volumn 39, Issue 5, 2011, Pages 379-395

  Amanfu, Robert K ^a   Saucerman, Jeffrey J ^a  

^a University of Virginia   (United States)

Author keywords

Arrhythmia; Cell signaling; Computational modeling; Electrophysiology; Metabolism

Indexed keywords

CARDIOLOGY; CELL SIGNALING; COMPUTATION THEORY; DISEASE CONTROL; DISEASES; DRUG PRODUCTS; ELECTROPHYSIOLOGY; METABOLISM; NEUROLOGY; PHYSIOLOGY;

ARRHYTHMIA; CARDIAC DISEASE; CARDIAC RHYTHMS; CARDIO-VASCULAR DISEASE; CAUSES OF DEATH; CELLULAR MODEL; COMPUTATIONAL MODEL; DRUG DEVELOPMENT;

HEART;

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE I; CYCLIC AMP; ISOPRENALINE; MEXILETINE; NS 1643; NS1643; PHOSPHOLAMBAN; PINACIDIL; PROPRANOLOL; PROTEIN SERINE THREONINE KINASE INHIBITOR; RANOLAZINE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SOTALOL; UNCLASSIFIED DRUG;

ARTICLE; CELL METABOLISM; DISEASE MODEL; DRUG DEVELOPMENT; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; IC 50; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84555195746     PISSN: 0278940X     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevBiomedEng.v39.i5.30     Document Type: Article

References (130)

1. Noble D. Cardiac action and pacemaker potentials based on the Hodgkin-Huxley equations. Nature. 1960;188:495-7.
2. Fink M, Noble D. Pharmacodynamic effects in the cardiovascular system: the modeller's view. Basic Clin Pharmacol Toxicol. 2010;106(3):243-9.
3. Reumann M, Gurev V, Rice JJ. Computational modeling of cardiac disease: potential for personalized medicine. Pers Med. 2009;6(1):45-66.
4. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart Disease and Stroke Statistics-2010 Update A Report From the American Heart Association. Circulation. 2010;121(7):E46-E215.
5. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and Morbidity in patients receiving encainide, flecainide, or placebo---the Cardiac-Arrhythmia Suppression Trial. New Engl J Med. 1991;324(12):781-8.
6. Foody JM, Farrell MH, Krumholz HM. betablocker therapy in heart failure. Scientific review. JAMA. 2002;287(7):883-9.
7. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10): 1013-22.
8. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151-85.
9. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-5.
10. Rodriguez B, Burrage K, Gavaghan D, Grau V, Kohl P, Noble D. The systems biology approach to drug development: application to toxicity assessment of cardiac Drugs. Clin Pharmacol Ther. 2010;88(1):130-4.
11. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008;59:1-12.
12. US Food and Drug Administration. FDA's Critical Path Initiative. Updated November 17, 2011. http://www.fda.gov/ScienceResearch/Special-Topics/CriticalPathInitiative/default.htm. Accessed November 21, 2011.
13. Lesko LJ. Paving the critical path: How can clinical pharmacology help achieve the vision? Clin Pharmacol Ther. 2007;81(2):170-7.
14. Hunter PJ, Viceconti M. The VPH-Physiome Project: Standards and tools for multiscale modeling in clinical applications. IEEE Rev Biomed Eng. 2009;(2):40-53.
15. Cho CR, Labow M, Reinhardt M, van Oostrum J, Peitsch MC. The application of systems biology to drug discovery. Curr Opin Chem Biol. 2006;10(4):294-302.
16. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415(6868):198-205.
17. Modell SM, Lehmann MH. The long QT syndrome family of cardiac ion channelopathies: A HuGE review. Genet Med. 2006;8(3):143-55.
18. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. New Engl J Med. 2003;348(19):1866-74.
19. Jordan PN, Christini DJ. Therapies for ventricular cardiac arrhythmias. Crit Rev Biomed Eng. 2005;33(6):557-604.
20. Beeler GW, Reuter H. Reconstruction of the action potential of ventricular myocardial fibres. J Physiol. 1977;268(1):177-210.
21. Luo CH, Rudy Y. A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction. Circ Res. 1991;68(6):1501-26.
22. Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. Circ Res. 1994;74(6):1097-113.
23. Jafri MS, Rice JJ, Winslow RL. Cardiac Ca2+ dynamics: the roles of ryanodine receptor adaptation and sarcoplasmic reticulum load. Biophys J. 1998;74(3):1149-68.
24. Williams GS, Smith GD, Sobie EA, Jafri MS. Models of cardiac excitation-contraction coupling in ventricular myocytes. Math Biosci. 2010;226(1):1-15.
25. Gadsby DC. Ion channels versus ion pumps: the principal difference, in principle. Nat Rev Mol Cell Biol. 2009;10(5):344-52.
26. Rudy Y, Silva JR. Computational biology in the study of cardiac ion channels and cell electrophysiology. Q Rev Biophys. 2006;39(1):57-116.
27. Fink M, Noble D. Markov models for ion channels: versatility versus identifiability and speed. Philos Transact A Math Phys Eng Sci. 2009;367(1896):2161-79.
28. Pugsley MK. Antiarrhythmic drug development: Historical review and future perspective. Drug Develop Res. 2002;55(1):3-16.
29. Zareba W, Moss AJ, Locati EH, et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol. 2003;42(1):103-9.
30. Bennett PB, Yazawa K, Makita N, George AL. Molecular mechanism for an inherited cardiacarrhythmia. Nature. 1995;376(6542):683-5.
31. Clancy CE, Zhu ZI, Rudy Y. Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol. 2007;292(1):H66-75.
32. Clancy CE, Rudy Y. Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation. 2002;105(10):1208-13.
33. Moreno JD, Clancy CE. Using computational modeling to predict arrhythmogenesis and antiarrhythmic therapy. Drug Discov Today Dis Models. 2009;6(3):71-84.
34. Priebe L, Beuckelmann DJ. Simulation study of cellular electric properties in heart failure. Circ Res. 1998;82(11):1206-23.
35. ten Tusscher KH, Noble D, Noble PJ, Panfilov AV. A model for human ventricular tissue. Am J Physiol Heart Circ Physiol. 2004;286(4):H1573-89.
36. Iyer V, Mazhari R, Winslow RL. A computational model of the human left-ventricular epicardial myocyte. Biophys J. 2004;87(3):1507-25.
37. Grandi E, Pasqualini FS, Bers DM. A novel computational model of the human ventricular action potential and Ca transient. J Mol Cell Cardiol. 2010;48(1):112-21.
38. Ten Tusscher KH, Bernus O, Hren R, Panfilov AV. Comparison of electrophysiological models for human ventricular cells and tissues. Prog Biophys Mol Biol. 2006;90(1-3):326-45.
39. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148(1):16-24.
40. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80(5):795-803.
41. Recanatini M, Cavalli A, Masetti M. Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations. Chem Med Chem. 2008;3(4):523-35.
42. London B, Trudeau MC, Newton KP, et al. Two isoforms of the mouse ether-a-go-go-related gene coassemble to form channels with properties similar to the rapidly activating component of the cardiac delayed rectifier K+ current. Circ Res. 1997;81(5):870-8.
43. Sale H, Wang JL, O'Hara TJ, et al. Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with long-QT syndrome. Circ Res. 2008;103(7): E81-E95.
44. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm. 2005;2(2 Suppl):S9-15.
45. Campbell SG, Flaim SN, Leem CH, McCulloch AD. Mechanisms of transmurally varying myocyte electromechanics in an integrated computational model. Philos Transact A Math Phys Eng Sci. 2008;366(1879):3361-80.
46. Pereon Y, Demolombe S, Baro I, Drouin E, Charpentier F, Escande D. Differential expression of KvLQT1 isoforms across the human ventricular wall. Am J Physiol Heart Circ Physiol. 2000;278(6):H1908-15.
47. Antzelevitch C. M cells in the human heart. Circ Res. 2010;106(5):815-7.
48. Brennan T, Fink M, Stokeley D, Rodriguez B, Tarassenko L. Modelling effects of sotalol on T-wave morphology. Presented at the 34th Annual Computers in Cardiology Conference; Durham, NC, September 30 through October 3, 2007;249-52.
49. Brennan T, Fink M, Rodriguez B, Tarassenko L. Modelling effects of Sotalol on Action Potential morphology using a novel Markov model of the HERG channel. 11th Mediterranean Conference on Medical and Biomedical Engineering and Computing Berlin, Heidelberg: Springer; 2007:50-3.
50. Peitersen T, Grunnet M, Benson AP, Holden AV, Holstein-Rathlou NH, Olesen SP. Computational analysis of the effects of the hERG channel opener NS1643 in a human ventricular cell model. Heart Rhythm. 2008;5(5):734-41.
51. Hansen RS, Diness TG, Christ T, et al. Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol Pharmacol. 2006;69(1):266-77.
52. Casis O, Olesen SP, Sanguinetti MC. Mechanism of action of a novel human ether-a-go-gorelated gene channel activator. Mol Pharmacol. 2006;69(2):658-65.
53. Mirams GR, Cui Y, Sher A, et al. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res. 2011;91:53-61.
54. Rodriguez B, Trayanova N, Noble D. Modeling cardiac ischemia. Ann N Y Acad Sci. 2006;1080:395-414.
55. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol. 2004;555(Pt 1):1-13.
56. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J Clin Invest. 2005;115(9):2305-15.
57. Carmeliet E. Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol Rev. 1999;79(3):917-1017.
58. Doenst T, Bugger H, Schwarzer M, Faerber G, Borger MA, Mohr FW. Three good reasons for heart surgeons to understand cardiac metabolism. Eur J Cardiothorac Surg. 2008;33(5):862-71.
59. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007;356(11):1140-51.
60. Shaw RM, Rudy Y. Electrophysiologic effects of acute myocardial ischemia: a theoretical study of altered cell excitability and action potential duration. Cardiovasc Res. 1997;35(2):256-72.
61. Cascio WE, Johnson TA, Gettes LS. Electrophysiologic changes in ischemic ventricular myocardium: I. Influence of ionic, metabolic, and energetic changes. J Cardiovasc Electrophysiol. 1995;6(11):1039-62.
62. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 1983;305(5930):147-8.
63. D'Alonzo AJ, Darbenzio RB, Hess TA, Sewter JC, Sleph PG, Grover GJ. Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia. Cardiovasc Res. 1994;28(6):881-7.
64. D'Alonzo AJ, Zhu JL, Darbenzio RB, Dorso CR, Grover GJ. Proarrhythmic effects of pinacidil are partially mediated through enhancement of catecholamine release in isolated perfused guinea-pig hearts. J Mol Cell Cardiol. 1998;30(2):415-23.
65. Trenor B, Ferrero JM Jr, Rodriguez B, Montilla F. Effects of pinacidil on reentrant arrhythmias generated during acute regional ischemia: a simulation study. Ann Biomed Eng. 2005;33(7): 897-906.
66. Ferrero JM Jr, Saiz J, Ferrero JM, Thakor NV. Simulation of action potentials from metabolically impaired cardiac myocytes. Role of ATP-sensitive K+ current. Circ Res. 1996;79(2):208-21.
67. Ch'en FFT, Vaughan-Jones RD, Clarke K, Noble D. Modelling myocardial ischaemia and reperfusion. Prog Biophys Mol Bio. 1998;69(2-3):515-38.
68. DiFrancesco D, Noble D. A model of cardiac electrical activity incorporating ionic pumps and concentration changes. Philos Trans R Soc Lond B Biol Sci. 1985;307(1133):353-98.
69. Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart. 2006;92(Suppl 4):iv1-iv5.
70. Michailova A, McCulloch A. Model study of ATP and ADP buffering, transport of Ca(2+) and Mg(2+), and regulation of ion pumps in ventricular myocyte. Biophys J. 2001;81(2):614-29.
71. Puglisi JL, Wang F, Bers DM. Modeling the isolated cardiac myocyte. Prog Biophys Mol Biol. 2004;85(2-3):163-78.
72. Cortassa S, Aon MA, O'Rourke B, Jacques R, Tseng HJ, Marban E, et al. A computational model integrating electrophysiology, contraction, and mitochondrial bioenergetics in the ventricular myocyte. Biophys J. 2006;91(4):1564-89.
73. Cortassa S, Aon MA, Marban E, Winslow RL, O'Rourke B. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J. 2003;84(4):2734-55.
74. Beard DA. Modeling of oxygen transport and cellular energetics explains observations on in vivo cardiac energy metabolism. Plos Computational Biology. 2006;2(9):1093-106.
75. Wu F, Zhang JY, Beard DA. Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism. P Natl Acad Sci USA. 2009;106(17): 7143-8.
76. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature. 2008;451(7181):919-28.
77. Wallis J, Lygate CA, Fischer A, ten Hove M, Schneider JE, Sebag-Montefiore L, et al. Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure. Insights from creatine transporter-overexpressing transgenic mice. Circulation. 2005;112(20):3131-9.
78. Salazar NC, Chen J, Rockman HA. Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta. 2007;1768(4):1006-18.
79. Schaub MC, Hefti MA, Zaugg M. Integration of calcium with the signaling network in cardiac myocytes. Journal of Molecular and Cellular Cardiology. 2006;41(2):183-214.
80. Bers DM, Guo T. Calcium signaling in cardiac ventricular myocytes. Ann Ny Acad Sci. 2005;1047:86-98.
81. Maier LS. CaMKII delta overexpression in hypertrophy and heart failure: cellular consequences for excitation-contraction coupling. Braz J Med Biol Res. 2005;38(9):1293-302.
82. Bers DM, Grandi E. Calcium/calmodulin-dependent kinase ii regulation of cardiac ion channels. J Cardiovasc Pharm. 2009;54(3):180-7.
83. Livshitz LM, Rudy Y. Regulation of Ca2+ and electrical alternans in cardiac myocytes: role of CAMKII and repolarizing currents. Am J Physiol Heart Circ Physiol. 2007;292(6):H2854-66.
84. Hund TJ, Rudy Y. Rate dependence and regulation of action potential and calcium transient in a canine cardiac ventricular cell model. Circulation. 2004;110(20):3168-74.
85. Hund TJ, Rudy Y. A role for calcium/calmodulin-dependent protein kinase II in cardiac disease and arrhythmia. Handb Exp Pharmacol. 2006;(171):201-20.
86. Erickson JR, Joiner ML, Guan X, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell. 2008;133(3):462-74.
87. Christensen MD, Dun W, Boyden PA, Anderson ME, Mohler PJ, Hund TJ. Oxidized calmodulin kinase II regulates conduction following myocardial infarction: a computational analysis. PLoS Comput Biol. 2009;5(12):e1000583.
88. Ursell PC, Gardner PI, Albala A, Fenoglio JJ Jr, Wit AL. Structural and electrophysiological changes in the epicardial border zone of canine myocardial infarcts during infarct healing. Circ Res. 1985;56(3):436-51.
89. Veeraraghavan R, Poelzing S. Mechanisms underlying increased right ventricular conduction sensitivity to flecainide challenge. Cardiovasc Res. 2008;77(4):749-56.
90. Zhang R, Khoo MS, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005;11(4):409-17.
91. Saucerman JJ, McCulloch AD. Cardiac betaadrenergic signaling: from subcellular microdomains to heart failure. Ann N Y Acad Sci. 2006;1080:348-61.
92. Saucerman JJ, Brunton LL, Michailova AP, Mc-Culloch AD. Modeling beta-adrenergic control of cardiac myocyte contractility in silico. J Biol Chem. 2003;278(48):47997-8003.
93. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res. 2003;93(10):896-906.
94. Hoch B, Meyer R, Hetzer P, Krause EG, Karczewski P. Identification and expression of delta-isoforms of the multifunctional Ca2+/ calmodulin-dependent protein kinase in failing and nonfailing human myocardium. Circ Res. 1999;84(6):713-21.
95. Curran J, Hinton MJ, Rios E, Bers DM, Shannon TR. Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res. 2007;100(3):391-8.
96. Soltis AR, Saucerman JJ. Synergy between CaMKII substrates and C-adrenergic signaling in regulation of cardiac myocyte Ca2+ handling. Biophys J. 2010;99:2038-47.
97. Marx SO, Kurokawa J, Reiken S, et al. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science. 2002;295(5554):496-9.
98. Saucerman JJ, Healy SN, Belik ME, Puglisi JL, McCulloch AD. Proarrhythmic consequences of a KCNQ1 AKAP-binding domain mutation: computational models of whole cells and heterogeneous tissue. Circ Res. 2004;95(12):1216-24.
99. Darbar D, Roden DM, Ali MF, Yang T, Wathen MS. Images in cardiovascular medicine. Himalayan T waves in the congenital long-QT syndrome. Circulation. 2005;111(11):e161.
100. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol. 2000;35(3): 778-86.
101. Ahrens-Nicklas RC, Clancy CE, Christini DJ. Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling. Cardiovasc Res. 2009;82(3):439-47.
102. Faber GM, Rudy Y. Action potential and contractility changes in [Na(+)](i) overloaded cardiac myocytes: a simulation study. Biophys J. 2000;78(5):2392-404.
103. Splawski I, Timothy KW, Decher N, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A. 2005;102(23):8089-96; discussion 6-8.
104. Sung RJ, Wu YH, Lai NH, et al. Beta-adrenergic modulation of arrhythmogenesis and identification of targeted sites of antiarrhythmic therapy in Timothy (LQT8) syndrome: a theoretical study. Am J Physiol Heart Circ Physiol. 2010;298(1):H33-44.
105. Faber GM, Silva J, Livshitz L, Rudy Y. Kinetic properties of the cardiac L-type Ca2+ channel and its role in myocyte electrophysiology: A theoretical investigation. Biophysical Journal. 2007;92(5):1522-43.
106. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006;7(8):589-600.
107. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109(Suppl):S67-79.
108. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93(2):215-28.
109. Cooling M, Hunter P, Crampin EJ. Modeling hypertrophic IP3 transients in the cardiac myocyte. Biophys J. 2007;93(10):3421-33.
110. Leinwand LA. Calcineurin inhibition and cardiac hypertrophy: a matter of balance. Proc Natl Acad Sci U S A. 2001;98(6):2947-9.
111. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1(9):727-30.
112. Kumar N, Hendriks BS, Janes KA, de Graaf D, Lauffenburger DA. Applying computational modeling to drug discovery and development. Drug Discovery Today. 2006;11(17-18):806-11.
113. McGregor E, Dunn MJ. Proteomics of the heart-Unraveling disease. Circ Res. 2006;98(3):309-21.
114. Mervaala E, Biala A, Merasto S, Lempiainen J, Mattila I, Martonen E, et al. Metabolomics in Angiotensin II-Induced Cardiac Hypertrophy. Hypertension. 2010;55(2):508-15.
115. Winslow RL, Cortassa S, Greenstein JL. Using models of the myocyte for functional interpretation of cardiac proteomic data. J Physiol. 2005;563(1):73-81.
116. Winslow RL, Rice J, Jafri S, Marban E, O'Rourke B. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: Model studies. Circ Res. 1999;84(5): 571-86.
117. O'Rourke B, Kass DA, Tomaselli GF, Kaab S, Tunin R, Marban E. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: Experimental studies. Circ Res. 1999;84(5):562-70.
118. McGregor E, Dunn MJ. Proteomics of heart disease. Hum Mol Genet. 2003;12:R135-R44.
119. Berger SI, Ma'ayan A, Iyengar R. Systems Pharmacology of Arrhythmias. Sci Signal. 2010;3(118):ra30.
120. Pujol A, Mosca R, Farres J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci. 2010;31(3):115-23.
121. Ma XH, Shi Z, Tan CY, Jiang YY, Go ML, Low BC, et al. In-silico approaches to multi-target drug discovery. Pharm Res. 2010;27(5):739-49.
122. Noble D. Modeling the heart. Physiology (Bethesda). 2004;19:191-7.
123. Trayanova NA. Whole-heart modeling: applications to cardiac electrophysiology and electromechanics. Circ Res. 2011;108(1):113-28.
124. Potse M, Dube B, Richer J, Vinet A, Gulrajani RM. A comparison of monodomain and bidomain reaction-diffusion models for action potential propagation in the human heart. IEEE Trans Biomed Eng. 2006;53(12):2425-35.
125. Sato D, Xie YF, Weiss JN, Qu ZL, Garfinkel A, Sanderson AR. Acceleration of cardiac tissue simulation with graphic processing units. Med Biol Eng Comput. 2009;47(9):1011-5.
126. Vicini P. Multiscale modeling in drug discovery and development: future opportunities and present challenges. Clin Pharmacol Ther. 2010;88(1):126-9.
127. Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology, 11th edition. New York: McGraw-Hill Medical; 2009.
128. Michelson S, Sehgal A, Friedrich C. In silico prediction of clinical efficacy. Curr Opin Biotech. 2006;17(6):666-70.
129. Wu FT, Stefanini MO, MacGabhann F, Popel AS. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS One. 2009;4(4):e5108.
130. Niederer SA, Fink M, Noble D, Smith NP. A meta-analysis of cardiac electrophysiology computational models. Exp Physiol. 2009;94(5): 486-95.